# A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

Source: https://onco.cc/trials/nct06319820/  
OnCo record `nct06319820` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of TAR-210 and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, now recruiting.

## Summary

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer is a phase 3 interventional study registered as NCT06319820 by Janssen Research & Development, LLC, with 641 participants planned, started 2024-04-18 and due to reach its primary completion in 2028-06-28. Interventions recorded: TAR-210, Gemcitabine and MMC.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06319820
- Phase: 3
- Setting: A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 641

## Sources

- ClinicalTrials.gov NCT06319820: https://clinicaltrials.gov/study/NCT06319820

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [TAR-210](https://onco.cc/drugs/tar-210/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct06319820.json